Gastric outlet obstruction secondary to pancreatic cancer

Abstract

In pancreatic carcinoma patients with gastric outlet obstruction, duodenal stenting results in an earlier discharge from hospital and possibly improved survival.

Matched study of three methods for palliation of malignant pyloroduodenal obstruction

“…A recent study has suggested the opposite trend, with a median survival of 64 days for OGJ compared with 110 days for ES 13 . One of the limitations of the present study is the lack of pathological staging data on all patients.…”

Self-expandable metallic stents for palliation of patients with malignant gastric outlet obstruction caused by stomach cancer

“…Endoscopic stent placement is a safe and feasible treatment option for patients with malignant gastric outlet obstruction. In retrospective comparative studies, patients who underwent an open gastrojejunostomy had delayed oral intake after surgery [3] , higher procedure-related morbidity, higher 30-d mortality [4] , and a longer length of hospital stay [4][5][6] , and incurred greater hospital charges [5] than patients who underwent an endoscopic stent insertion. To date, there has been no study that assesses clinical outcome after SEMS insertion for malignant gastric outlet obstruction caused by stomach cancer only, rather than by pancreatic, biliary, or duodenal cancer.…”

Therapeutic, prophylactic, and preresection applications of laparoscopic gastric and biliary bypass for patients with periampullary malignancy

“…However, in the current era of minimally invasive management, the endoscopic application of selfexpandable duodenal metal stents [1,16,27] should be considered when laparoscopic surgery is contemplated. Duodenal stents have been associated with lower morbidity and shorter postintervention hospital stay than experienced with a laparotomy [27].…”

“…Duodenal stents have been associated with lower morbidity and shorter postintervention hospital stay than experienced with a laparotomy [27]. However, recurrence of the obstruction requiring reintervention has been reported in 17% to 27% of patients because tumor ingrowth into the stent or distal migration of a covered stent [1,10,16].…”